This study indicates that the proliferation inhibition of NB cells by BI-D1870 appears to be independent of whether the cells themselves are accompanied by MYCN gene amplification mutations, implying that it is likely that BI-D1870 can address the therapeutic challenge of high-risk NB with MYCN gene amplification, which is insensitive to conventional tumor chemotherapeutic agents. This evidence concerns the gene MYCN and neoplasm.